Product Program year 2023 Source: CMS Open Payments

Fetzima

Drug Neuroscience

NDC 0456-2240-30

Open in the dashboard

General payments

$5,027

8 payments

Research payments

$4,527,941

1,104 payments

Through program year 2023, $5,027 in general payments and $4,527,941 in research payments were reported against Fetzima (Neuroscience).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Amount Payments
2023 Research $2,600 1
2021 Research $43,720 39
2020 General $4,561 4
2020 Research $192,216 483
2019 General $466 4
2019 Research $4,289,405 581

Breakdown

Who paid General payments · program years 2019–2020
  1. Allergan Inc. $5,027 8 payments
Top recipients General payments · program year 2020
  1. Richard Mamelok Internal Medicine · Palo Alto, CA $4,500 99% · 2 payments
  2. Kimberly Clinebell Psychiatry · Pittsburgh, PA $49 1% · 1 payment
  3. Elizabeth Bailey Obstetrics & Gynecology · Richmond, TX $12 <1% · 1 payment

Each share is of general payments naming this product in 2020.

Specialties paid General payments · program year 2020
  1. Internal Medicine $4,500 99% · 1 practitioner
  2. Psychiatry Psychiatry & Neurology $49 1% · 1 practitioner
  3. Obstetrics & Gynecology $12 <1% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2020
  1. California $4,500 99% · 1 recipient
  2. Pennsylvania $49 1% · 1 recipient
  3. Texas $12 <1% · 1 recipient

Each share is of general payments naming this product in 2020 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

21,714

Prescriptions dispensed, refills included

Drug cost

$11,796,211

Paid at the pharmacy, in all

Prescribers

1,237

With 11 or more claims of it

Medicare Part D drugs matched to FETZIMA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Fetzima Levomilnacipran Hcl Same name 1,237 21,714 $11,796,211

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Alexander Pinkusovich Psychiatry NY 135 $65,486 None on record
Timothy Rasmussen Psychiatry MN 104 $52,267 None on record
John Ciaccio Psychiatry IL 77 $44,002 None on record
Julia Lansing Certified Clinical Nurse Specialist OH 75 $44,790 None on record
Joseph Luzius Psychiatry NM 69 $39,544 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
8 general · 1,104 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record